Targeting Circ‐OCAC suppress oral squamous cell carcinoma progression
Oral Diseases · 2024
DOI: 10.1111/odi.14687 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2024. Verfasst von Bowen Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, MicroRNAs, Mouth Neoplasms, RNA, Circular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Department of Health of Guangdong Province Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
Circular RNAs (circRNAs), with their multilevel and versatile regulation, have emerged as promising targets for treating complex and heterogeneous malignancies such as oral squamous cell carcinoma (OSCC). It is crucial to explore the function of key circRNAs and elucidate the underlying mechanisms to establish an effective in vivo delivery system to better utilize circRNAs as cancer treatment strategies. Materials and Methods circRNA (circ‐OCAC) was identified as significantly downregulated in tumor samples compared to paracancerous tissues by RNA‐seq analysis of eight pairs of OSCC tissues. Functional experiments of circ‐OCAC were performed both in vitro and in vivo . The interactions between circ‐OCAC and miR‐411‐5p were clarified by RNA pull down and RNA immunoprecipitation (RIP) assays.
Results
We observed that circ‐OCAC inhibits OSCC growth and metastasis by blocking the PI3K/Akt signaling pathway. To translate this observation in vivo, a pH‐responsive nanoparticle (pNP) was developed to target circ‐OCAC. Our results confirmed the advantages of the pNP‐circ‐OCAC system: high tumor enrichment capacity and good biosafety, which resulted in a significantly enhanced antitumor effect.
Conclusions
This study demonstrated that targeting circ‐OCAC serves as a promising potential therapeutic strategy for OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen Universi…
- Department of Oral and Maxillofacial Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
- Longgang E.N.T. Hospital & Shenzhen Key Laboratory of E.N.T, Institute of E.N.T, Shenzhen, Guangdong, China.
- Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Department of Pathology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Jinsong Li
Förderung
- China Postdoctoral Science Foundation
- Department of Health of Guangdong Province Science Foundation
- National Natural Science Foundation of China
- Shenzhen Innovation of Science and Technology Commission
- Shenzhen Science and Technology Program
- The Science and Technology Program of Guangzhou
Zitieren
APA
Li, B., Ding, Y., Huo, C., Ren, S., Chen, S., He, H., Li, S., Wang, X., Cen, M., Yang, H., & Li, J. (2024). Targeting Circ‐OCAC suppress oral squamous cell carcinoma progression. Oral Diseases. https://doi.org/10.1111/odi.14687
Vancouver
Li B, Ding Y, Huo C, Ren S, Chen S, He H, et al. Targeting Circ‐OCAC suppress oral squamous cell carcinoma progression. Oral Diseases. 2024. doi:10.1111/odi.14687
BibTeX
@article{Li2024,
author = {Li, Bowen and Ding, Yuxun and Huo, Chuying and Ren, Siqi and Chen, Suling and He, Haizhang and Li, Shurui and Wang, Xiaojuan and Cen, Meifeng and Yang, Hongyu and Li, Jinsong},
title = {Targeting Circ‐OCAC suppress oral squamous cell carcinoma progression},
journal = {Oral Diseases},
year = {2024},
doi = {10.1111/odi.14687}
}
EUVIMED